A phase 1, open-label, single-center, nonrandomized, 2-cohort study was conducted in healthy subjects: a single centre study

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 21 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Acalabrutinib (Primary) ; Acalabrutinib (Primary)
Indications B-cell lymphoma; B-cell prolymphocytic leukaemia; Bladder cancer; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Glioblastoma; Head and neck cancer; Mantle-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Rheumatoid arthritis; Waldenstrom's macroglobulinaemia
Focus Pharmacokinetics

01 Dec 2018 New trial record
15 Nov 2018 Results assesssing the pharmacokinetics of Acalabrutinib in healthy volunteers, published in the Drug Metabolism and Disposition.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com